Success Metrics

Completion Rate
0%(0/1)
Active Trials
6(86%)
Terminated
1(14%)

Phase Distribution

Ph phase_2
2
29%
Ph phase_1
5
71%

Phase Distribution

5

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
5(71.4%)
Phase 2Efficacy & side effects
2(28.6%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

6

trials recruiting

Total Trials

7

all time

Status Distribution
Active(6)
Terminated(1)

Detailed Status

Recruiting6
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
6
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 15 (71.4%)
Phase 22 (28.6%)

Trials by Status

terminated114%
recruiting686%

Recent Activity

6 active trials
Showing 5 of 7
recruitingphase_2

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

NCT06661915
recruitingphase_1

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

NCT06287775
recruitingphase_1

Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML

NCT06514261
recruitingphase_1

Iadademstat + SBRT With Atezo in ES-SCLC

NCT07113691
recruitingphase_1

Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia

NCT06357182
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT06661915Phase 2

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

Recruiting
NCT06287775Phase 1

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

Recruiting
NCT06514261Phase 1

Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML

Recruiting
NCT07113691Phase 1

Iadademstat + SBRT With Atezo in ES-SCLC

Recruiting
NCT06357182Phase 1

Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia

Recruiting
NCT05420636Phase 2

Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET

Terminated
NCT05546580Phase 1

Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)

Recruiting

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7